LAG3 and neoplasm: B16-F10 model mice treated with LAG-3-blockading antibody (monotherapy) only exhibited delayed tumor growth, whereas combination therapy targeting both LAG-3 and PD-1 at the time of relapse resulted in significant tumor regression [78].